Deferred Tax Assets, Valuation Allowance of CORCEPT THERAPEUTICS INC from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
CORCEPT THERAPEUTICS INC quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • CORCEPT THERAPEUTICS INC Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $20,926,000, a 20% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

CORCEPT THERAPEUTICS INC Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $20,926,000 +$3,466,000 +20% 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q4 2024 $17,460,000 +$1,513,000 +9.5% 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q4 2023 $15,947,000 +$1,108,000 +7.5% 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q4 2022 $14,839,000 +$1,867,000 +14% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q4 2021 $12,972,000 +$1,391,000 +12% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q4 2020 $11,581,000 +$171,000 +1.5% 31 Dec 2020 10-K 15 Feb 2022 2021 FY
Q4 2019 $11,410,000 +$226,000 +2% 31 Dec 2019 10-K 23 Feb 2021 2020 FY
Q4 2018 $11,184,000 -$1,290,000 -10% 31 Dec 2018 10-K 24 Feb 2020 2019 FY
Q4 2017 $12,474,000 -$116,895,000 -90% 31 Dec 2017 10-K 26 Feb 2019 2018 FY
Q4 2016 $129,369,000 -$4,281,000 -3.2% 31 Dec 2016 10-K 28 Feb 2018 2017 FY
Q4 2015 $133,650,000 -$2,419,000 -1.8% 31 Dec 2015 10-K 06 Mar 2017 2016 FY
Q4 2014 $136,069,000 +$15,900,000 +13% 31 Dec 2014 10-K 10 Mar 2016 2015 FY
Q4 2013 $120,169,000 +$15,920,000 +15% 31 Dec 2013 10-K 13 Mar 2015 2014 FY
Q4 2012 $104,249,000 +$14,001,000 +16% 31 Dec 2012 10-K 14 Mar 2014 2013 FY
Q4 2011 $90,248,000 31 Dec 2011 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.